KBC Group NV lifted its holdings in ResMed Inc. (NYSE:RMD) by 20.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,733 shares of the medical equipment provider’s stock after buying an additional 5,521 shares during the period. KBC Group NV’s holdings in ResMed were worth $2,519,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of the company. BlackRock Inc. lifted its stake in shares of ResMed by 6.8% in the second quarter. BlackRock Inc. now owns 14,240,077 shares of the medical equipment provider’s stock worth $1,108,877,000 after buying an additional 904,939 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of ResMed by 3.3% in the second quarter. Vanguard Group Inc. now owns 11,914,671 shares of the medical equipment provider’s stock worth $927,797,000 after buying an additional 378,964 shares in the last quarter. FMR LLC lifted its stake in shares of ResMed by 38.2% in the second quarter. FMR LLC now owns 5,542,582 shares of the medical equipment provider’s stock worth $431,601,000 after buying an additional 1,531,772 shares in the last quarter. Baillie Gifford & Co. raised its stake in ResMed by 0.9% during the third quarter. Baillie Gifford & Co. now owns 4,913,626 shares of the medical equipment provider’s stock worth $378,154,000 after purchasing an additional 44,340 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in ResMed by 1.2% during the second quarter. Bank of New York Mellon Corp now owns 2,266,663 shares of the medical equipment provider’s stock worth $176,505,000 after purchasing an additional 25,925 shares during the period. 62.02% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have commented on RMD shares. Northland Securities reaffirmed a “sell” rating and set a $55.00 target price on shares of ResMed in a research note on Friday, October 27th. Zacks Investment Research raised shares of ResMed from a “sell” rating to a “hold” rating in a research note on Monday, October 30th. Barclays lifted their target price on shares of ResMed from $65.00 to $68.00 and gave the stock an “underweight” rating in a research note on Monday, September 25th. Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a research note on Friday, October 27th. Finally, J P Morgan Chase & Co lifted their target price on shares of ResMed from $72.00 to $73.00 and gave the stock an “overweight” rating in a research note on Monday, October 30th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. ResMed presently has an average rating of “Hold” and an average target price of $67.57.
In other news, Director Peter C. Farrell sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $77.01, for a total value of $1,540,200.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Peter C. Farrell sold 118,392 shares of the business’s stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $82.70, for a total transaction of $9,791,018.40. Following the completion of the sale, the director now directly owns 306,615 shares in the company, valued at $25,357,060.50. The disclosure for this sale can be found here. Insiders sold a total of 184,693 shares of company stock worth $15,149,955 over the last three months. Insiders own 1.77% of the company’s stock.
Shares of ResMed Inc. (NYSE:RMD) traded up $0.60 during mid-day trading on Friday, reaching $86.37. 546,820 shares of the company’s stock were exchanged, compared to its average volume of 552,324. The company has a quick ratio of 3.86, a current ratio of 4.72 and a debt-to-equity ratio of 0.50. ResMed Inc. has a one year low of $60.13 and a one year high of $87.81. The stock has a market capitalization of $12,256.25, a P/E ratio of 30.09, a PEG ratio of 1.92 and a beta of 0.78.
ResMed (NYSE:RMD) last released its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.66. The business had revenue of $523.66 million for the quarter, compared to the consensus estimate of $506.08 million. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The business’s revenue was up 12.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.62 EPS. analysts anticipate that ResMed Inc. will post 3 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 14th. Stockholders of record on Thursday, November 9th will be paid a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.62%. The ex-dividend date is Wednesday, November 8th. ResMed’s dividend payout ratio (DPR) is 56.68%.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/10/kbc-group-nv-boosts-stake-in-resmed-inc-rmd.html.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.